Disease |
Disease |
Method |
Sample |
Expression pattern |
Dysfunction type |
Description |
PMID |
Source |
esophageal squamous cell carcinoma |
qPCR, knockdown etc. |
esophageal suqmous cell cancer tissue, cell lines (KYSE30, KYSE70, KYSE140, KYSE150, KYSE180 etc.) |
up-regulated |
expression |
Notably elevated FOXCUT and FOXC1 expression levels were observed in cancerous tissues compared to adjacent noncancerous tissues, showing strong correlations with poor differentiation, advanced lymph node classification and metastasis. The expression of FOXCUT was positively correlated with expression of FOXC1 in ESCC specimens. And the expression of FOXC1 was also decreased as the FOXCUT expression was silenced by siRNA. Assays in vitro demonstrated that knockdown of either FOXCUT or FOXC1 remarkably inhibited cell proliferation, colony formation, migration, invasion in ESCC cells. |
25031703 |
Lnc2Cancer
|
basal-like breast cancer |
qPCR, knockdown etc. |
cell lines (MDA-MB-231, MDA-MB-468) |
up-regulated |
interaction |
The results showed that the expression of FOXCUT and FOXC1 were positively correlated. When the expression of FOXCUT was downregulated by small interfering RNA, the expression of FOXC1 was similarly reduced. Furthermore, in MDA-MB-231 and MDA-MB-468 breast cancer cells, knockdown of FOXCUT markedly inhibited cell proliferation and migration in vitro. In conclusion, FOXCUT lncRNA may be functionally involved in the tumor progression of BLBCs through the regulation of its paired mRNA, FOXC1, demonstrating that FOXCUT may serve as a novel biomarker and therapeutic target in BLBCs. |
25516208 |
Lnc2Cancer
|
oral squamous cell carcinoma |
qPCR, Western blot, knockdown etc. |
OSCC tissue, cell lines (Tca8113, OSC-4, SCC1 etc.) |
up-regulated |
N/A |
In this study, we report a new lncRNA FOXC1 upstream transcript (FOXCUT) that was remarkably overexpressed in 23 OSCC patients, as was the adjacent FOXC1 gene. The expressions of FOXC1 and FOXCUT were positively correlated. In conclusion, FOXC1 may be co-amplified with FOXCUT in OSCC, and both of them may be functionally involved in the tumor progression of OSCC. |
24889262 |
Lnc2Cancer
|
|